Poolbeg Pharma Ltd. (GB:POLB) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Poolbeg Pharma Ltd has secured an exclusive option to acquire a new treatment for Behçet’s Disease from Silk Road Therapeutics, aiming to address the unmet medical need for this condition that currently lacks a cure. The treatment, a novel topical formulation of Pentoxifylline, has shown promise in a Phase 2 trial, outperforming the standard care by accelerating the healing of oral ulcers. With secured Fast Track and Orphan Drug Designations from the FDA, Poolbeg Pharma is now conducting due diligence to ascertain the clinical approval pathway for potential expedited U.S. approval.
For further insights into GB:POLB stock, check out TipRanks’ Stock Analysis page.